Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.
It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Founded
1998
Employees
28
Headquarters
Calgary, AB T2R 0C5, Canada
Loading company sections...
⚡
Core Efficiency
D/E Ratio?
-3.00
📊
Profitability Ratios
Current Ratio?
1.12
Loading comparison...
Earnings Calendar
Filing history and next expected filing date
Next Expected Filing
Aug 22, 2026 (in 88 days)
Annual Report (10-K) — Estimated
Aug 22, 2026
Predicted10-K
Mar 30, 2026
10-KQ4 20257d after period end
Data Freshness
Financial Data
1mo ago
Latest filing: 2026-03-30
SEC Metadata
2mo ago
Recent Insider Trades
Kelly Jared — Purchase 5,050 shares at $0.96 on 2026-03-12
Parsons James T. — Purchase 10,000 shares at $1.03 on 2026-03-11
Andrews Patricia S — Purchase 35,400 shares at $0.86 on 2026-02-12
Brown Deborah Margaret — Purchase 25,000 shares at $0.85 on 2026-02-12
